Zobrex Dosage/Direction for Use

Celecoxib capsules, at dose up to 200 mg twice per day can be taken with or without food. As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Symptomatic Treatment of Osteoarthritis (OA): The usual recommended dose of celecoxib is 200 mg administered as a single dose. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after 2 weeks, other therapeutic options should be considered.
Symptomatic Treatment of Rheumatoid Arthritis (RA): The recommended dose of celecoxib is 200 mg twice per day.
Ankylosing Spondylitis (AS): The recommended dose of celecoxib is 200 mg administered as a single dose. If no response is observed after 6 weeks, the dosage may be increased to 400 mg daily.
Management of Acute Pain: The recommended dose of celecoxib is 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Treatment of Primary Dysmenorrhea: The recommended dose of celecoxib is 400 mg initially, followed by an additional 200 mg dose, if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily or 400 mg once daily as needed.
Low Back Pain (LBP): The recommended dose of celecoxib is 200 mg or 400 mg daily, administered as a 200 mg single dose, or as 100 or 200 mg twice per day. Some patients may benefit from a total daily dose of 400 mg.
CYP2C9 Poor Metabolizers: Patients who are known, or suspected to be CYP2C9 poor metabolizers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution. Consider starting treatment at half the lowest recommended dose.
Co-administration with Fluconazole: Celecoxib should be introduced at half the recommended dose in patients receiving fluconazole, a CYP2C9 inhibitor. Caution is advised when co-administering celecoxib with other CYP2C9 inhibitors.
Elderly: Dose adjustment in the elderly is not generally necessary. However, for patients less than 50 kg in body weight, initiate therapy at the lowest recommended dose or as directed by the physicians.
Hepatic Impairment: Dose adjustment in the patients with mild hepatic impairment is not generally necessary. Treatment should be initiated at half of the recommended dose in patients with established moderate liver impairment with serum albumin of 25-35 g/l. There is no clinical experience in patients with severe hepatic impairment.
Renal Impairment: Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore, such patients should be treated with caution. There is no clinical experience in patients with severe renal impairment.
Children: There are no adequate data from the use of celecoxib in children under 18 years. Celecoxib should not be used in children.